News Story: Full Text
Sponsored By
Cedars-Siani Medical Center Brain Tumor Program
Please Click On The Above Banner For More Details
Braintumor Website

 

Merck KGaA brain tumor drug fails clinical trial

Al's Comment:

  There was a lot of hope for this drug. Failing the clinical trial does not mean that it is useless. It means that it didn't work in the manner that they used it, which is in combination with the standard treatments.  This drug has many effects on the tumor cells: it inhibits cell migration, differentiation,  angiogenesis, wound healing, immune and non-immune defense mechanisms, and oncogenic transformation.

  It's place may be in combination with other targeted agents and/or vaccines in a well thought out cocktail approach. I hope research on this continues.


Posted on: 02/25/2013

Merck KGaA brain tumor drug fails clinical trial

 
 

FRANKFURT (Reuters) - Merck KGaA's Cilengitide, an experimental drug to treat an aggressive type of brain tumor, has failed a large-scale clinical trial, dealing a blow to the German drugmaker's efforts to replenish its pipeline of medicines.

Merck said on Monday patients in a Phase III trial did not live significantly longer when treated with Cilengitide plus chemoradiotherapy.

Dr. Annalisa Jenkins, Head of Global Drug Development and Medical for the Merck Serono division, said the trial results were "disappointing, especially for people who are fighting this devastating and difficult to treat cancer".

For Merck, Germany's oldest drugmaker, the latest findings come after its experimental cancer vaccine Stimuvax failed in a Phase III trial last December.

In 2011, Merck's Cladribin, a treatment for multiple sclerosis, also failed.

Last month, Chief Executive Stefan Oschmann said in magazine interview that Merck needed a new drug every two years, with the focus on cancer, immune-deficiencies, multiple sclerosis and fertility.

At 0925 GMT, Merck shares were down 0.6 percent at 105 euros.

At the Phase III trial of Cilengitide, the patients had newly diagnosed Glioblastoma - a very aggressive brain tumor - and methylated MGMT gene promoter status.

Cilengitide is the first in a new class of investigational targeted anticancer therapies - so called integrin inhibitors - to have reached Phase III clinical development.

(Reporting by Marilyn Gerlach; Editing by Mark Potter)

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740